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1109-9666/ª 2016 Hellenic Cardiologi
license (http://creativecommons.org/Abstract Treating patients known to have immune thrombocytopenic purpura (ITP) present-
ing with acute coronary syndrome (ACS) pose challenges, especially if they undergo percuta-
neous coronary intervention and stenting, as they require certain period of dual anti-
platelet medication based up on the type of stent been deployed. Co-existence of therapies
to increase platelet number as well as anti-platelet efficacy at the same time appears contra-
dictory; imbalance in antagonistic treatment approach of increasing platelet number to treat
ITP and inhibiting their activity to treat ACS can result in life threatening complications.
ª 2016 Hellenic Cardiological Society. Publishing services by Elsevier B.V. This is an open ac-
cess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).1. Introduction
Immune thrombocytopenic purpura (ITP), characterized by
immune-mediated premature platelet destruction, resultsah, Cardiology Department,
N, Canada. Tel.: þ1 416 835
ail.com (A.H. Shah).
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cal Society. Publishing services by
licenses/by-nc-nd/4.0/).in thrombocytopenia and bleeding complications.1 Those
presenting with the adult-onset, chronic form of ITP, which
is refractory to conventional treatment, have a higher
mortality rate, due to bleeding complications.2 Anti-
platelet medications are the most commonly used treat-
ment in patients with acute coronary syndrome (ACS) and
have been demonstrated to reduce secondary thrombotic
events and improve clinical outcomes.3,4 Treating patients
known to have ITP who present with ACS poses a major
challenge, especially if they undergo percutaneous coro-
nary intervention (PCI) and stenting, as they require a
certain period of dual anti-platelet medication (DAPT)Elsevier B.V. This is an open access article under the CC BY-NC-ND
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treatment approach of increasing platelet numbers to treat
ITP and inhibiting their activity to treat ACS can result in
life-threatening complications.
2. Case
A 42-year-old female presented with new-onset central,
squeezing chest pain and elevated troponin (troponin-I
0.35 ng/ml, normal<0.03 ng/ml). Electrocardiogram
demonstrated dynamic ‘T’ wave inversion in leads V1e4.
Trans-thoracic echocardiogram demonstrated mid and api-
cal anterior wall hypokinesia. She was known to have ITP
since 20 years of age. Over the years her treatment-
regimen required multiple changes to maintain a platelet
count of more than 30,000/mL, as drops in platelet counts
below 25,000/mL resulted in bleeding complications, mainly
petechia or menorrhagia. At the time of her presentation
with ACS she was managed with prednisolone and azathio-
prine. Previously, she required treatment with intra-venous
immunoglobulin (IVIg) infusion to treat ITP; and once, three
days after IVIg infusion, she suffered with deep vein
thrombosis (DVT). There was no apparent reason for her to
have limited mobility and thrombophilia screen was nega-
tive. DVTwas suspected to be due to IVIg treatment. From a
cardiovascular risk factors point of view, she was also
diagnosed with impaired glucose tolerance for nearly 10
years.
At the time of admission her platelet count was 35,000/
ml. As there were concerns with DAPT and heparin use, she
was treated with IVIg (1 gm/kg), in addition to routine use
of prednisolone and azathioprine. Forty-eight hours later
her platelet count increased to 85,000/ml and she was
taken to the cardiac catheterization laboratory. Coronary
angiography (CAG) demonstrated a moderate lesion in the
proximal-mid part of the left anterior descending (LAD)
artery (Fig. 1A). In view of a prognostically significant
lesion, PCI was performed using 3.023 mm Genous stent
(OrbusNeich, Ft. Lauderdale, FL, USA), (which is coated
with anti-CD34þ antibody that helps cover stent struts with
endothelial progenitor cells, promoting earlier strut
coverage and reduced risk of thrombosis), and eventually
required a short duration of DAPT use, up to 1 week.5,6 PCI
was successfully completed and good final results were
achieved (Fig. 1C).
She was discharged home 48 hours post PCI with advice
for long-term aspirin use and clopidogrel for 28 days. She
represented back to hospital on the night of her discharge
with anterior ST elevation myocardial infarction (STEMI).
Primary-PCI call was activated; CAG demonstrated her to
have in-stent thrombosis (ST) (Fig. 1D). She was treated
with thrombus aspiration and further stenting with two
3.513 mm Genous stents (Fig. 1E and F). Platelet count
on the day of stent thrombosis was 135,000/ml, and this
time her clopidogrel was changed for ticagrelor.
As we wanted to minimize the duration of DAPT, the
patient was brought back to the catheterization laboratory
for repeat CAG, and optical coherence tomography (OCT),
six weeks from her re-do PCI. The OCT examination sug-
gested satisfactory stent strut coverage; and therefore, she
was advised to stop ticagrelor (Fig. 1GeJ). However,despite the apparent stent strut coverage, the patient was
readmitted with further chest pain and troponin rise
(1.76 mg/ml) seven days later, and the CAG demonstrated
patent stents and no further intervention was required.
Ultimately, ticagrelor was recommended for 12-months
with long-term aspirin. During this 12-month period, while
she was on DAPT, her platelet count was carefully managed
with the use of prednisolone, azathioprine and romiplos-
tim. At 12-months the ticagrelor was stopped and she has
remained asymptomatic for more than 2 years.
3. Discussion
There is a lack of “evidence based treatment” for patients
known to have ITP and presenting with ACS. Inhibiting
platelet-aggregation, especially when the platelet count is
very low, is a challenging situation for the treating clini-
cian. This case raises many questions, including (1) What
should be the ideal minimum platelet count when treating
such patients with DAPT for ACS/post-PCI? (2) What are the
ideal anti-platelet therapies to be used in such patients? (3)
What was the mechanism of ST in this patient? And most
importantly: (4) How do we avoid bleeding/thrombotic
complications, while maintaining adequate platelet count
and continuing with DAPT?
While treating patients with ITP, platelet counts are
aimed to be maintained between 30 and 50,000/mL.1 There
is no consensus on minimum acceptable platelet count level
while treating ITP patients presenting with ACS. Throm-
botic events are reported in patients not only with throm-
bocytosis7 but also with thrombocytopenia associated with
various conditions.8 One should not be preoccupied with
platelet count alone, as platelet functions are not affected
merely by a change in their numbers; but at the same time
it is equally difficult to commence DAPT, when platelet
count is very low, as bleeding can result in fatal conse-
quences. Identifiable markers to assess platelet activity in
such patients are lacking, and platelet function assays have
not even been validated for use in patients with thrombo-
cytopenia. Evidence-based DAPT combination in treating
patients with ITP is unknown.
Multiple factors may have played a role leading to ST in
this patient and can be divided into factors related to ITP or
PCI. Use of IVIg has been associated with arterial/venous
thrombotic events, mainly at the time of infusion or up to 8
days after the infusion.9 In our patient, the thrombotic
event occurred four days after IVIg infusion, and the
platelet count was the highest ever noted since she had
been undergoing treatment for ITP. Our patient also suf-
fered with DVT many years ago after IVIg treatment, and
her platelet counts were reportedly more than 100,000/ml
at that time. We were not aware of her history of DVT with
IVIg use, as the patient was treated in another hospital at
that time and she did not provide this information in her
history. Should we have known of this complication, we
would have avoided IVIg use, or may have kept the dose
very low. Thrombotic events in the form of ACS or stroke
have been reported in patients treated with IVIg, especially
with incremental platelet count and the presence of un-
derlying coronary artery disease. Based upon aggregometry
studies, the platelet agonist properties of IVIg have been
Figure 1 Index coronary angiography and PCI (AeC). A: lesion in mid LAD; B: Circumflex vessel free of disease; C: LAD post PCI.
Patient presented with stent thrombosis and was treated with PCI (DeF). D: Occluded LAD in stented segment; E: aspirated
thrombus; F: LAD post stenting. Check angio and OCT 5 weeks after second PCI for ST (GeJ). G: Circumflex vessel; H: LAD vessel; I:
OCT still frame in stented segment, demonstrating well covered stent struts; J: longitudinal view of OCT within the stented
segment.
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experiments have suggested that increments in blood and
plasma viscosity, beyond the normal range in response to
infused IVIg, may be responsible.11 The rise in platelet
number after IVIg is due to reduced antibody mediated
destruction; at the same time, platelets in patients with ITP
are young, freshly released from the bone-marrow and are
more functional than expected.12 A combination ofhyperactive and a large number of platelets can lead to
thrombotic complications. Additionally, ITP patients have
higher platelet-derived micro-particles (PMP)13 that have
the potential to promote pro-coagulant activity.14
Alternatively, uncovered or mal-opposed stent struts
could have resulted in stent thrombosis. Intra-coronary
imaging to understand the underlying mechanism should
have been performed at the time of presentation with ST,
276 A.H. Shah et al.rather than additional stent deployment. After repeat PCI
for ST, patient was treated with aspirin and ticagrelor for 12
months, along with prednisolone, azathioprine and romi-
plostim to maintain platelet count, which were closely
monitored and medications were adjusted accordingly.
Although ITP is associated with significant risk of
bleeding, major bleeding is rare. Interestingly, patients
with ITP are also likely to suffer with complications that
arise from the treatment toward maintaining higher
platelet count, i.e., long-term side effects of steroids or
elevated risk of infection post-splenectomy.
4. Conclusions
A rising platelet count in response to IVIg treatment may
represent a highly thrombotic milieu and extra care should
be taken, especially in those with underlying atheroscle-
rotic disease. ITP patients presenting with ACS can be
treated with DAPT and PCI, and the aim should be to
minimize DAPT duration with close monitoring of platelet
counts and associated bleeding complications.
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